Abeona Therapeutics Inc.
$4.65+6.7%YTD-12.3%1Y-15.9%
Price updated 12h ago·X counts updated 4d ago
On X
The complete picture of $ABEO on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.
29X posts · last 7 days
Chatter Meter
0.9×
How loud $ABEO's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.
AI verdictAI analysisGenerated by AI from underlying data
TickerTalks' own read on what's driving $ABEO — fundamentals, momentum, or an event — and whether it agrees with the X crowd.
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Biotechnology sits in its cycle right now — and what that implies for $ABEO.
Biotechnology
No material change from last week — mRNA oncology platform remains the structural driver.
What this means for $ABEO
Partial — Clinical-stage gene and cell therapy biotech targeting rare genetic skin and metabolic diseases with next-gen delivery platforms.
Top industry ETF
$IBBiShares Biotechnology ETF
+17.9%YTD
+35.2%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
5.8How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
-50.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
-6.4%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
-20.2%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
29.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
41.4%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
51.9%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
0.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q2 2026Aug 13, 2026$-0.35$-0.23-51.1%
Q1 2026May 13, 2026$-0.30$-0.33+9.1%
Q4 2025Mar 17, 2026$-0.34$-0.35+2.9%
Q3 2025Nov 12, 2025$-0.10$-0.27+63.0%
Next earningsWed, Nov 11·consensus EPS $-0.14
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$8.7M—59.1%-264%$-0.30$-20.7M
Q4 FY25$5.4M—47.7%-423%$-0.39$-19.1M
Q3 FY25$0———$-0.10$-23.7M
Q2 FY25$400K—75.0%-5698%$2.07$-21.7M
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$52.6M$43.3M – $68.1M-$0.97-$1.26 – -$0.557
FY27$115.6M$84.7M – $164.1M-$0.18-$1.00 – $1.007
FY28$188.6M$139.1M – $227.0M$0.39-$0.46 – $1.106
FY29$282.7M$208.6M – $368.9M$1.43$0.94 – $2.004
FY30$329.7M$243.3M – $430.3M$2.16$1.42 – $3.013
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.18%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-18.7%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-16.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FloatLow float · 36.9M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today3.7% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.305-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.
Insider activity
Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.
SEC filings
Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.
Recent material filings
8-KPress release / Reg FDSep 158-K — Item 7.01: Press release / Reg FD
AI summary
8-KShareholder voteJun 128-K — Item 5.07: Shareholder vote
8-KOfficer or director changeJun 128-K — Item 5.02: Officer or director change
8-KPress release / Reg FDJun 108-K — Item 7.01: Press release / Reg FD
+ 13 other (4 13Gs · 2 10-Qs · 2 earnings 8-Ks · 2 proxys) in window
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEOAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEOINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEOINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
More in Biotechnology
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · last 7 days
No standout posts about $ABEO on X in the last 7 days.